{
    "nctId": "NCT04664829",
    "briefTitle": "The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC",
    "officialTitle": "Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells From a Mesenchymal-Like to an Epithelial-Like Phenotype",
    "overallStatus": "RECRUITING",
    "conditions": "Metastatic Triple-Negative Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "Tumour transcriptome by RNA sequencing",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with histologically or cytologically proven metastatic TNBC\n* Patients whose TNBC has progressed after prior taxane therapy in the (neo)adjuvant or metastatic setting, and have not received Capecitabine or 5-fluorouracil\n* Females aged 21 years and older\n* ECOG performance status 0 or 1\n* Life expectancy greater than three months\n* Patients have normal organ and marrow function\n* Site(s) of disease amenable to serial bedside biopsies before, during and after study treatment\n\nExclusion Criteria:\n\n* Previous palliative radiotherapy to potentially biopsy-able lesion\n* Active symptomatic central nervous system (CNS) metastases\n* Spinal cord compression not definitively treated with surgery and/or radiation\n* Uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent drainage procedures",
    "sex": "FEMALE",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}